Catalyst Pharmaceuticals Inc (CN2 F) stock market data APIs
€21.75
-1.18(-5.1%)
as of February 6, 2025
Catalyst Pharmaceuticals Inc Financial Data Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Prev. Close
23.31
Open
21.75
High
23.4
Low
22.3
52 wk Range
12.275-22.93
Market Cap
2 735 M
P/E Ratio
19.2689
Shares Outstanding
119 M
Revenue
460 M
EPS
0.11
Beta
0.755
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Catalyst Pharmaceuticals Inc data using free add-ons & libraries
Get Catalyst Pharmaceuticals Inc Fundamental Data
Catalyst Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 460 M
- EBITDA: 211 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-09
- EPS/Forecast: 0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Catalyst Pharmaceuticals Inc News
New
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point. Continue Reading View Comments
Harmony Biosciences Stock Scores 80-Plus RS Rating
The Relative Strength (RS) Rating for Harmony Biosciences stock jumped into a new percentile Thursday, with an increase from 70 to 83. This proprietary rating tracks market leadership by showing how a...
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among t...
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. While you may have an investing style you rely on...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
